In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.
BMY-28100 was compared with cephalexin, cefaclor, cefixime, and cefteram and found to be more active than the reference cephalosporins against Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus faecalis, and Clostridium difficile. BMY-28100 was the next most active, after cefteram, against Streptococcus pyogenes and Streptococcus pneumoniae. Against gram-negative bacteria, BMY-28100 showed similar activity to that of cefaclor. The antimicrobial activity of BMY-28100, including bactericidal activity, against Staphylococcus aureus was less affected by penicillinase-production than was that of cefaclor. BMY-28100 was more stable than cefaclor against various types of penicillinases, especially against the penicillinase from Staphylococcus aureus.
D002433:Cefaclor / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D003013:Clostridium / Q000187:drug effects; D004755:Enterobacteriaceae / Q000187:drug effects; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006193:Haemophilus influenzae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D010405:Penicillinase / Q000378:metabolism*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D000097670:Cefprozil
D002433:Cefaclor; D002511:Cephalosporins; D010405:Penicillinase; D000097670:Cefprozil